Aptevo Therapeutics Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Grant Grady III, was filed 12 Nov 2025.
Who traded when
BuySaleSince the insiders bought
- -73.4%Entry US$26.10 · Close at T+90 US$6.95
- -19.5%Entry US$6,399,993.50 · Close at T+365 US$5,151,643.00
- -29.3%Entry US$6,129,224.50 · Close at T+365 US$4,331,131.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- 400 sharesCommon StockSEC:0001193125-26-343069:0
- 400 sharesCommon StockSEC:0001193125-26-343065:0
- 400 sharesCommon StockSEC:0001193125-26-343067:0
- 1 sharesCommon StockSEC:0001193125-26-343070:0
- 400 sharesCommon StockSEC:0001193125-26-343072:0
- 1,666 sharesCommon StockSEC:0001193125-26-343070:1
- 638 sharesCommon StockSEC:0001193125-26-343073:0
- 638 sharesCommon StockSEC:0001193125-26-343076:0
- 638 sharesCommon StockSEC:0001193125-26-343077:0
- 961 sharesCommon StockSEC:0001193125-26-343079:0
- 400 sharesCommon StockSEC:0001193125-26-343080:0
- 156 shares@ US$4.070.018% mcap100.0% of flowCommon StockSEC:0001193125-26-343073:1
- 406 shares@ US$4.070.048% mcap100.0% of flowCommon StockSEC:0001193125-26-343070:2
- 13,513 shares@ US$1.49100.0% of flowCommon StockSEC:0001193125-25-277771:0Canonical exit: 8 Feb 2026 (T+90)
- 5 sharesCommon Stock (post-reverse split May ACTIVE)SEC:0000950170-25-097267:0
- 1 sharesCommon StockSEC:0000950170-25-097283:0
- 1 sharesCommon StockSEC:0000950170-25-097280:0
- 1 sharesCommon StockSEC:0000950170-25-097279:0
- 1 sharesCommon StockSEC:0000950170-25-097278:0
- 1 sharesCommon StockSEC:0000950170-25-097274:0
- 3 sharesCommon StockSEC:0000950170-25-097272:0
- 3 sharesCommon StockSEC:0000950170-25-097271:0
- 10 sharesCommon StockSEC:0000950170-25-097269:0
- 6 sharesCommon StockSEC:0000950170-25-032187:1
- 2 sharesCommon StockSEC:0000950170-25-032201:1
25 of 205 declarations
About Aptevo Therapeutics Inc.
Kevin C. Tang, a holder of more than 10% of Aptevo Therapeutics Inc., signs 33 of the 205 filings in the record, 16 purchases and 17 sales, and holds the largest amounts on each side. His three largest purchases follow one another over three days in November 2020: EUR 2,430,704 on the 5th, EUR 2,290,725 on the 4th and EUR 2,143,861 on the 6th. His three largest sales, from November 23, 2021, reach EUR 1,940,484, EUR 1,791,864 and EUR 1,484,088.
In all, 41 purchases represent EUR 18,383,915 (median EUR 36,795) and 17 sales EUR 14,964,900 (median EUR 1,123,130), so purchases are 71% of market trades by count. Jeffrey G. Lamothe, President and CEO, signs 30 filings with no purchase or sale, Marvin L. White, Executive Chair, 21, of which 5 purchases, and Fuad El-Hibri, a director, 13, of which 10 purchases. Between May 31 and June 25, 2019, 6 filers bought EUR 107,969.
Read moreShow less
The record covers 205 filings from August 2, 2016 to August 10, 2026, including 115 option exercises and 25 grants. This US health care company, listed on Nasdaq, is valued at USD 2.9 million; insiders hold 4.2% of it. Across 39 purchases with a 90-day return, the stored median is -8.8% (past results on record, not a forecast).
